AstraZeneca PLC AZN
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
AstraZeneca PLC is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $243.3B, based in the USA.
It employs about 96,100 people and has been listed since May 17, 1993.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 23.6 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 6% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 14.6 — they expect higher earnings.
The average analyst price target is 212.17, 35% above the current price (their view, not ours).
The stock sits at 8% of its one-year range (0% = the low, 100% = the high).
The risks
- No risk flags were detected from the data we have.
Strengths
- ✅ Profitable — 16 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (10 vs 0).
- ✅ Pays a dividend (2.0% a year).
What changed this week
Over the past week the stock fell 5.8% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- 3 British AI Healthcare Stocks With Revenue Up To £61 Billion finance.yahoo.com · 2026-10-03
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot seekingalpha.com · 2026-10-03
- Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets finance.yahoo.com · 2026-10-03
- Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration finance.yahoo.com · 2026-10-02
- Sector Update: Healthcare Stocks Steady Late Afternoon finance.yahoo.com · 2026-10-02
- AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3 finance.yahoo.com · 2026-10-02
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.